MassDevice.com +5 | The top 5 medtech stories for December 20, 2016

Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. 21st Century Cures Act adds Hatch-Waxman rule to drug-device combos Section 3038 of the 21st Century Cures Act applies Hatch-Waxman rules to certain drug-device combination products, addressing the regulatory pathway for devices that incorporate already approved drugs. The Hatch-Waxman Act, named for Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.), was approved in 1984. It was designed to make it easier for generic drugs to enter the market by requiring manufacturers to submit an abbreviated new drug application and prove their drug’s bioequivalence to the original branded drug. This meant generic drug makers would not have to endure the laborious and costly process of clinical studies. Read more 4. Study: Laser-activated deep-sea drug kills prostate cancer Researchers from the Weizmann Institute of Science and Steba Biotech have reportedly developed a light-sensitive drug derived from deep-sea bacteria that has been shown to kill cancer cells in low-risk prostate cancer patients without affecting healthy tissue. The team’s work was published in Lancet Oncol...
Source: Mass Device - Category: Medical Equipment Authors: Tags: News Well Plus 5 Source Type: news